1Elevan Biopharmaceuticals

1Elevan Biopharmaceuticals, Inc. is a peptide therapeutics company advancing FDA-approved and expanded-access peptides for chronic and complex diseases.

Founded with a vision to modernise medicine, 1Elevan Biopharmaceuticals is dedicated to developing precision peptide therapeutics that target natural disease pathways. The company focuses on FDA-approved and FDA-expanded-access peptides, aiming to deliver safer, more effective treatments than traditional small-molecule drugs. By emphasising high regulatory standards and patient-centred innovation, 1Elevan seeks to transform care in areas such as transplant, endocrinology, neurology, oncology, cardiology, nephrology, orthopedics, sports medicine, wellness, and longevity. As operations begin in Fishers, Indiana, in autumn 2025, the business remains rooted in cutting‑edge science and collaborative, compassionate biotechnology.

Key Products and Services

• FDA‑approved and FDA‑expanded‑access peptide therapeutics addressing chronic and serious conditions.
• Precision peptide design and development targeting specific disease mechanisms.
• Advanced medication delivery systems engineered for improved safety and efficacy.
• Pharmacy operations including Category III, 503A/503B compounding services.
• Telemedicine support for peptide therapy management and prescriptions.
• Contract development and manufacturing (CDMO) services for peptide drug production.

With a launch site in Fishers set to open in late 2025, 1Elevan Biopharmaceuticals is positioned to deliver a full continuum of peptide therapy development, from early research through clinical manufacturing and patient services. Supported by a team of experts and strategic expansion across the US, the company aims to transform peptide-based care and enhance patient access to innovative treatments.